HAMBURG, Germany – Shares of Vital Therapies Inc. (NASDAQ:VTL), which plunged on Sept. 12 after bad news about its ELAD liver therapy (extracorporeal liver-assist device), were hammered yet again, closing at $0.35 on Sept. 14 as the company ponders its future.